As mentioned, this compound is pre-clinical. We all know how long it takes to bring the compound to market. I personally see it as a 2nd generation compound in Rett`s. In my book this agreement / license is a long-term investment from Acadia. By the time this compound potentially hits the market, they probably have lost the Trof patent protection.
One side note is, that they still spend money on in-licensing. Which begs the question of their plans towards potentially buying NEU. If they do buy NEU, they might need to do a CAP raise again?
DYOR.
ACADIA PARTNERSHIP STOKE THERAPEUTICS, page-5
-
- There are more pages in this discussion • 33 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$15.48 |
Change
0.160(1.04%) |
Mkt cap ! $1.978B | |||
| Open | High | Low | Value | Volume |
| $15.10 | $15.48 | $15.04 | $6.154M | 402.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1498 | $15.45 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $15.50 | 8296 | 2 |
View Market Depth
| Last trade - 16.10pm 21/08/2024 (20 minute delay) ? |
| NEU (ASX) Chart |